Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F4NS
|
|||
| Former ID |
DNC004616
|
|||
| Drug Name |
Mozavaptan
|
|||
| Synonyms |
137975-06-5; Opc-31260; Opc 31260; Mozavaptan [INN]; CHEMBL420762; OPC31260; 5-Dimethylamino-1-(4-(2-methylbenzoylamino)benzoyl)-2,3,4,5-tetrahydro-1H-benzazepine; N-(4-(5-(dimethylamino)-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carbonyl)phenyl)-2-methylbenzamide; N-(4-((5-(Dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl)phenyl)-2-methylbenzamide; N-(4-(((5RS)-5-(Dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl)phenyl)-2-methylbenzamide; C27H29N3O2; OPC-31260
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hyponatraemia [ICD-11: 5C72; ICD-10: E87.1] | Approved | [1], [2], [3] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C27H29N3O2
|
|||
| Canonical SMILES |
CC1=CC=CC=C1C(=O)NC2=CC=C(C=C2)C(=O)N3CCCC(C4=CC=CC=C43)N(C)C
|
|||
| InChI |
1S/C27H29N3O2/c1-19-9-4-5-10-22(19)26(31)28-21-16-14-20(15-17-21)27(32)30-18-8-13-24(29(2)3)23-11-6-7-12-25(23)30/h4-7,9-12,14-17,24H,8,13,18H2,1-3H3,(H,28,31)
|
|||
| InChIKey |
WRNXUQJJCIZICJ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 137975-06-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7980203, 10238465, 14929794, 29300265, 49876628, 50784549, 57339461, 85210057, 85856507, 92251402, 92720235, 103283744, 103938054, 104408167, 118843944, 125340574, 126522418, 126584454, 126620153, 126667663, 129623867, 131298331, 134341821, 135075013, 135650774, 137249480, 142385824, 152035180, 162009841, 162011504, 164826782, 170466304, 172914187, 174527391, 179149887, 206246079, 211535800, 223434818, 223658567, 225355504, 227838631, 241033722, 242059895, 252215844, 252472557
|
|||
| ChEBI ID |
CHEBI:135694
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vasopressin V1 receptor (V1R) | Target Info | Antagonist | [4] |
| Vasopressin V1a receptor (V1AR) | Target Info | Inhibitor | [5], [6] | |
| Vasopressin V1b receptor (V1BR) | Target Info | Inhibitor | [6] | |
| Vasopressin V2 receptor (V2R) | Target Info | Inhibitor | [5], [6], [7], [8] | |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Vascular smooth muscle contraction | ||||
| Vasopressin-regulated water reabsorption | ||||
| Pathwhiz Pathway | Vasopressin Regulation of Water Homeostasis | |||
| Pathway Interaction Database | Arf6 trafficking events | |||
| Reactome | Vasopressin-like receptors | |||
| G alpha (q) signalling events | ||||
| G alpha (s) signalling events | ||||
| Vasopressin regulates renal water homeostasis via Aquaporins | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Regulation of Water Balance by Renal Aquaporins | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001739) | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2197). | |||
| REF 4 | Vasopressin (ADH). Nippon Rinsho. 1992 Dec;50(12):2893-900. | |||
| REF 5 | Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene. Exp Clin Endocrinol Diabetes. 1999;107(3):157-65. | |||
| REF 6 | New analgesic drugs derived from phencyclidine. J Med Chem. 1981 May;24(5):496-9. | |||
| REF 7 | Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210. | |||
| REF 8 | Effects of an oral vasopressin receptor antagonist (OPC-31260) in a dog with syndrome of inappropriate secretion of antidiuretic hormone. Aust Vet J. 2000 Dec;78(12):825-30. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.